Sensitive and reliable PCR and sequencing used to detect p53 point mutations in fine needle aspirates of the breast

Journal of Clinical Pathology

Volumn 49, Issue 7, 1996, Pages 570-573

  Howes, G P ^a   Stephenson, J ^b   Humphreys, S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Department of Haematology ^*

Author keywords

Breast cancer; Fine needle aspiration; p53; Point mutation

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P53;

ARTICLE; ASPIRATION BIOPSY; ASPIRATION CYTOLOGY; BREAST BIOPSY; BREAST LESION; CANCER GRADING; CONTROLLED STUDY; DNA SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REPRODUCIBILITY;

EID: 0030036135     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.7.570     Document Type: Article

References (21)

1. Dowell SP, Wilson POG, Derias NW, Lane DP, Hall PA. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 1994; 54:2914-8.
2. Wells CA, Ellis IO, Zakhour HD, Wilson AR. Guidelines for cytology procedures and reporting on fine needle aspirates of the breast. Cytopathology 1994;5:316-34.
3. Stephenson TJ, Royds JA, Silcocks PB, Brammer HJ, Shorthouse AJ, Underwood JCE. Diagnostic associations of p53 immunostaining in fine needle aspiration cytology of the breast. Cytopathology 1994;5:146-53.
4. Báttek J, Bártková J, Vojtesek B, Stasková Z, Rejthar A, Kovarik J, et al. Patterns of expression of the p53 tumour suppressor in human breast tissues and its tumours in situ and in vitro. Int J Cancer 1990;46:839-14.
5. Levine AJ, Chang A, Dittmer D, Notterman DA, Silver A, Thorn K, et al. The p53 tumour suppressor gene. J Lab Clin Med 1994;123:817-23.
6. Tsuda H, Iwaya K, Fukutomi T, Hirohashi S. P53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 1993;84:394-401.
7. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis. Hum Pathol 1993;24:469-76.
8. Bozzetti C, Nizzoli R, Naldi N, Manotti L, Savoldi L, Camisa R, et al. Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma. Breast Cancer Res Treat 1994;32:221-8.
9. Wood WC. Integration of risk factors to allow patient selection for adjuvant systemic therapy in lymph node-negative breast cancer patients. World J Surg 1994;18:39-44.
10. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39-47.
11. Ljung B, Chew K, Deng G, Matsumura K, Waldman F, Smith H. Fine needle aspiration techniques for the characterization of breast cancers. Cancer 1994;74:1000-5.
12. Kovach JS, McGovern RM, Cassady JD, Swanson SK, Wold LE, Vogelstein B, et al. Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas. J Natl Cancer Inst 1991; 83:1004-9.
13. Cariello NF, Cui L, Beroud C, Soussi T. Database and software for the analysis of mutations in the human p53 gene. Cancer Res 1994;54:4454-60.
14. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Ueda R. p53 mutations in non-small-cell lung cancer in Japan: association between mutations and smoking. Cancer Res 1992;52:734-6.
15. Sander CA, Yano T, Clark HM, Hams C, Longo DL, Jaffe ES, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993;82:1994-2004.
16. De-Angelis P, Stokke T, Smedshammer L, Lothe RA, Meling GI, Rofstad MYC. P53 expression is associated with a high degree of tumor DNA aneuploidy and incidence of p53 gene mutation, and is localized to the aneuploid compartment in colorectal carcinomas. Int J Oncol 1993;3:305-12.
17. Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroeder JJ, Wold LE, et al. Pattern of p53 gene mutations in breast cancers of women of the Midwestern United States. J Natl Cancer Inst 1992;84:246-52.
18. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/hsp70 complexes in breast cancers. Proc Natl Acad Sci USA 1992;89:3439-42.
19. Lowe SW, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 1993;74:957-67.
20. Makris A, Powles TJ, Dowsett M, Allred C. p53 protein overexpression and chemosensitivity in breast cancer. Lancet 1995;345:1181-2.
21. Petty RD, Cree IA, Sutherland LA, Hunter EM, Lane DP, Preece PE, et al. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun 1994;199:264-70.